Skip to main content

Using Virtual Cancer Patients to Probe the Mechanisms of Oncology Drug Disposition

Oncology drug developers face a distinct set of challenges. Oncology drugs are often very toxic which precludes conducting clinical trials in healthy volunteers. In addition, cancer patients differ from healthy people in terms of their demographics and physiology. These changes mean that the pharmacokinetics of drugs may be altered in this population compared to healthy … Continued

1 of 1
Powered by GlobalLink OneLink Software